Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Revisiting progesterone receptor (PR) actions in breast cancer: Insights into PR repressive functions.

Proietti CJ, Cenciarini ME, Elizalde PV.

Steroids. 2018 May;133:75-81. doi: 10.1016/j.steroids.2017.12.015. Epub 2018 Jan 6. Review.

PMID:
29317254
2.

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.

Mercogliano MF, Inurrigarro G, De Martino M, Venturutti L, Rivas MA, Cordo-Russo R, Proietti CJ, Fernández EA, Frahm I, Barchuk S, Allemand DH, Figurelli S, Deza EG, Ares S, Gercovich FG, Cortese E, Amasino M, Guzmán P, Roa JC, Elizalde PV, Schillaci R.

BMC Cancer. 2017 Dec 28;17(1):895. doi: 10.1186/s12885-017-3897-x.

3.

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.

Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K.

Cancer Res. 2018 Feb 1;78(3):671-684. doi: 10.1158/0008-5472.CAN-17-1327. Epub 2017 Dec 6.

4.

Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway.

Velásquez LN, Milillo MA, Delpino MV, Trotta A, Mercogliano MF, Pozner RG, Schillaci R, Elizalde PV, Giambartolomei GH, Barrionuevo P.

Immunol Cell Biol. 2017 Apr;95(4):388-398. doi: 10.1038/icb.2016.111. Epub 2016 Nov 29.

PMID:
27811842
5.

ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.

Elizalde PV, Cordo Russo RI, Chervo MF, Schillaci R.

Endocr Relat Cancer. 2016 Dec;23(12):T243-T257. Epub 2016 Oct 7. Review.

PMID:
27765799
6.

TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.

Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R.

Clin Cancer Res. 2017 Feb 1;23(3):636-648. doi: 10.1158/1078-0432.CCR-16-0970. Epub 2016 Oct 3.

7.

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

Venturutti L, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV.

Oncogene. 2016 Dec 1;35(48):6189-6202. doi: 10.1038/onc.2016.151. Epub 2016 May 9.

8.

Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

Proietti CJ, Izzo F, Díaz Flaqué MC, Cordo Russo R, Venturutti L, Mercogliano MF, De Martino M, Pineda V, Muñoz S, Guzmán P, Roa JC, Schillaci R, Elizalde PV.

Mol Endocrinol. 2015 Oct;29(10):1468-85. doi: 10.1210/me.2015-1170. Epub 2015 Sep 4.

9.

Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Venturutti L, Romero LV, Urtreger AJ, Chervo MF, Cordo Russo RI, Mercogliano MF, Inurrigarro G, Pereyra MG, Proietti CJ, Izzo F, Díaz Flaqué MC, Sundblad V, Roa JC, Guzmán P, Bal de Kier Joffé ED, Charreau EH, Schillaci R, Elizalde PV.

Oncogene. 2016 Apr 28;35(17):2208-22. doi: 10.1038/onc.2015.281. Epub 2015 Jul 27.

PMID:
26212010
10.

Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride.

Wiebe JP, Rivas MA, Mercogliano MF, Elizalde PV, Schillaci R.

J Steroid Biochem Mol Biol. 2015 May;149:27-34. doi: 10.1016/j.jsbmb.2015.01.004. Epub 2015 Jan 13.

PMID:
25595041
11.

Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ.

Breast Cancer Res. 2014 Dec 6;16(6):491. doi: 10.1186/s13058-014-0491-x.

12.

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.

Cordo Russo RI, Béguelin W, Díaz Flaqué MC, Proietti CJ, Venturutti L, Galigniana N, Tkach M, Guzmán P, Roa JC, O'Brien NA, Charreau EH, Schillaci R, Elizalde PV.

Oncogene. 2015 Jun;34(26):3413-28. doi: 10.1038/onc.2014.272. Epub 2014 Sep 1.

PMID:
25174405
13.

Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.

Díaz Flaqué MC, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo R, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano M, Charreau EH, Yankilevich P, Schillaci R, Elizalde PV.

Breast Cancer Res. 2013 Dec 17;15(6):R118. doi: 10.1186/bcr3587.

14.

p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth.

Tkach M, Rosemblit C, Rivas MA, Proietti CJ, Díaz Flaqué MC, Mercogliano MF, Beguelin W, Maronna E, Guzmán P, Gercovich FG, Deza EG, Elizalde PV, Schillaci R.

Endocr Relat Cancer. 2013 Mar 22;20(2):197-212. doi: 10.1530/ERC-12-0194. Print 2013 Apr.

PMID:
23329648
15.

Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2.

Diaz Flaqué MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV.

Steroids. 2013 Jun;78(6):559-67. doi: 10.1016/j.steroids.2012.11.003. Epub 2012 Nov 21.

PMID:
23178160
16.

Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells.

Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Díaz Flaqué MC, Beguelin W, Frahm I, Charreau EH, Cassataro J, Elizalde PV, Schillaci R.

J Immunol. 2012 Aug 1;189(3):1162-72. doi: 10.4049/jimmunol.1102538. Epub 2012 Jun 29.

17.

Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV.

Breast Cancer Res. 2012 May 14;14(3):R77.

18.

The molecular basis of progesterone receptor action in breast carcinogenesis.

Elizalde PV, Proietti CJ.

Horm Mol Biol Clin Investig. 2012 Apr;9(2):105-17. doi: 10.1515/hmbci-2011-0129.

PMID:
25436702
19.

Influence of conformationally restricted pyrimidines on the activity of 10-23 DNAzymes.

Robaldo L, Izzo F, Dellafiore M, Proietti C, Elizalde PV, Montserrat JM, Iribarren AM.

Bioorg Med Chem. 2012 Apr 15;20(8):2581-6. doi: 10.1016/j.bmc.2012.02.047. Epub 2012 Feb 28.

PMID:
22429508
20.

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer.

Schillaci R, Guzmán P, Cayrol F, Beguelin W, Díaz Flaqué MC, Proietti CJ, Pineda V, Palazzi J, Frahm I, Charreau EH, Maronna E, Roa JC, Elizalde PV.

BMC Cancer. 2012 Feb 22;12:74. doi: 10.1186/1471-2407-12-74.

21.

[Teratogenic effect of misoprostol: a prospective study in Argentina].

de Elizalde P.

Arch Argent Pediatr. 2011 Dec;109(6):558; author reply 559. Spanish. No abstract available.

PMID:
22329074
22.

Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.

Durfort T, Tkach M, Meschaninova MI, Rivas MA, Elizalde PV, Venyaminova AG, Schillaci R, François JC.

PLoS One. 2012;7(1):e29213. doi: 10.1371/journal.pone.0029213. Epub 2012 Jan 3.

23.

Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer.

Proietti CJ, Béguelin W, Flaqué MC, Cayrol F, Rivas MA, Tkach M, Charreau EH, Schillaci R, Elizalde PV.

Steroids. 2011 Mar;76(4):381-92. doi: 10.1016/j.steroids.2010.12.008. Epub 2010 Dec 22. Erratum in: Steroids. 2011 Nov;76(12):1407.

PMID:
21184768
24.

Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3.

Béguelin W, Díaz Flaqué MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, Rosemblit C, Tocci JM, Charreau EH, Schillaci R, Elizalde PV.

Mol Cell Biol. 2010 Dec;30(23):5456-72. doi: 10.1128/MCB.00012-10. Epub 2010 Sep 27.

25.

Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation.

Rivas MA, Tkach M, Beguelin W, Proietti CJ, Rosemblit C, Charreau EH, Elizalde PV, Schillaci R.

Breast Cancer Res Treat. 2010 Jul;122(1):111-24. doi: 10.1007/s10549-009-0546-3. Epub 2009 Sep 18.

PMID:
19760502
26.

Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth.

Proietti CJ, Rosemblit C, Beguelin W, Rivas MA, Díaz Flaqué MC, Charreau EH, Schillaci R, Elizalde PV.

Mol Cell Biol. 2009 Mar;29(5):1249-65. doi: 10.1128/MCB.00853-08. Epub 2008 Dec 22.

27.

TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways.

Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R.

Exp Cell Res. 2008 Feb 1;314(3):509-29. Epub 2007 Oct 13.

PMID:
18061162
28.

Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.

Carnevale RP, Proietti CJ, Salatino M, Urtreger A, Peluffo G, Edwards DP, Boonyaratanakornkit V, Charreau EH, Bal de Kier Joffé E, Schillaci R, Elizalde PV.

Mol Endocrinol. 2007 Jun;21(6):1335-58. Epub 2007 Apr 17.

PMID:
17440047
29.

Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.

Salatino M, Beguelin W, Peters MG, Carnevale R, Proietti CJ, Galigniana MD, Vedoy CG, Schillaci R, Charreau EH, Sogayar MC, Elizalde PV.

Oncogene. 2006 Dec 14;25(59):7723-39. Epub 2006 Jun 26.

PMID:
16799639
30.
31.

Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells.

Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, Kornblihtt AR, Molinolo AA, Frahm I, Charreau EH, Schillaci R, Elizalde PV.

Mol Cell Biol. 2005 Jun;25(12):4826-40.

32.

[Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer].

Salatino M, Schillaci R, Proietti CJ, Carnevale R, Charreau EH, Elizalde PV.

Medicina (B Aires). 2004;64(2):129-34. Spanish.

PMID:
15628299
33.
34.

Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas.

Daroqui MC, Puricelli LI, Urtreger AJ, Elizalde PV, Lanuza GM, Bal de Kier Joffé E.

Breast Cancer Res Treat. 2003 Aug;80(3):287-301.

PMID:
14503801
35.

Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.

Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR, Charreau EH, Elizalde PV.

Mol Cell Biol. 2003 Feb;23(3):1095-111.

36.

Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.

Puricelli L, Proietti CJ, Labriola L, Salatino M, Balañá ME, Aguirre Ghiso J, Lupu R, Pignataro OP, Charreau EH, Bal de Kier Joffé E, Elizalde PV.

Int J Cancer. 2002 Aug 20;100(6):642-53. Erratum in: Int J Cancer. 2005 Dec 20;117(6):1065. Proiettii, Cecilia J [corrected to Proietti, Cecilia J].

37.

Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors.

Salatino M, Labriola L, Schillaci R, Charreau EH, Elizalde PV.

Exp Cell Res. 2001 Apr 15;265(1):152-66.

PMID:
11281653
38.

Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.

Balañá ME, Labriola L, Salatino M, Movsichoff F, Peters G, Charreau EH, Elizalde PV.

Oncogene. 2001 Jan 4;20(1):34-47.

PMID:
11244498
39.
40.
41.

Differential expression of and responsiveness to transforming growth factor-beta (TGF-beta) isoforms in hormone-dependent and independent lines of mouse mammary tumors.

Viegas MH, Salatino M, Goin M, Peters G, Labriola L, Costa da cunha J, Lanari C, Charreau EH, Elizalde PV.

Cancer Detect Prev. 1999;23(5):375-86.

PMID:
10468889
42.

Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas.

Elizalde PV, Lanari C, Molinolo AA, Guerra FK, Balañá ME, Simian M, Iribarren AM, Charreau EH.

J Steroid Biochem Mol Biol. 1998 Nov;67(4):305-17.

PMID:
9883987
43.

Promoter effect of medroxyprogesterone acetate (MPA) in N-methyl-N-nitrosourea (MNU) induced mammary tumors in BALB/c mice.

Pazos P, Lanari C, Elizalde P, Montecchia F, Charreau EH, Molinolo AA.

Carcinogenesis. 1998 Mar;19(3):529-31.

PMID:
9525291
44.

[Growth hormones and oncogenes in mammary adenocarcinomas induced by medroxyprogesterone acetate in BALB/c mice].

Elizalde PV, Balaña ME, Charreau EH.

Medicina (B Aires). 1997;57 Suppl 2:70-4. Spanish.

PMID:
9580484
45.

Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability.

Guerra FK, Eijan AM, Puricelli L, Alonso DF, Bal de Kier Joffé E, Kornblihgtt AR, Charreau EH, Elizalde PV.

Int J Cancer. 1996 Mar 15;65(6):812-20.

46.

Correlation of TGF-beta 1 expression with medroxyprogesterone acetate responsiveness in mouse mammary adenocarcinomas.

Elizalde PV, Guerra FK, Gravano M, Lanari C, Lippman ME, Charreau EH, Lupu R.

Cancer Invest. 1995;13(2):173-80.

PMID:
7874571
47.

Effect of sialoadenectomy on medroxyprogesterone-acetate-induced mammary carcinogenesis in BALB/c mice. Correlation between histology and epidermal-growth-factor receptor content.

Kordon EC, Guerra F, Molinolo AA, Elizalde P, Charreau EH, Pasqualini CD, Montecchia F, Pazos P, Dran G, Lanari C.

Int J Cancer. 1994 Oct 15;59(2):196-203.

PMID:
7927919
48.

Enhanced expression of angiotensin II receptor subtypes and angiotensin converting enzyme in medroxyprogesterone-induced mouse mammary adenocarcinomas.

Guerra FK, Ciuffo GM, Elizalde PV, Charreau EH, Saavedra JM.

Biochem Biophys Res Commun. 1993 May 28;193(1):93-9.

PMID:
8389152
49.

Estrogen inhibition of MPA-induced mouse mammary tumor transplants.

Kordon E, Lanari C, Molinolo AA, Elizalde PV, Charreau EH, Dosne Pasqualini C.

Int J Cancer. 1991 Dec 2;49(6):900-5.

PMID:
1835715
50.

Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate.

Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Dosne Pasqualini C.

Breast Cancer Res Treat. 1990 Nov;17(1):33-43.

PMID:
2151368

Supplemental Content

Loading ...
Support Center